Cancer screening biomarker
Due to scientific and clinical efforts, the death rate from cancer in the modern world is gradually decreasing. This advancement highly relies on finding cancers in the early-stage by use of cancer screening tests. Biomarker tests are quick and simple to find potential disease indicators in the patient's body, and it's possible to test multiple individuals at once. It helps to detect cancers and recurrence monitoring with simple testing methods and affordable cost benefiting many potential patients.
Selecting and accurately detecting appropriate biomarkers is essential for successful cancer screening. InnoBation Bio's YN522 biomarker shows comparative advantages in accuracy, assay time, and applicability to a variety of cancer types.
Cancer Screening Case 1 : Common Cancers
Cancer Screening Case 2 : Female Cancer
(BRC and OVC)
Our team have proven that YN522 is significantly decreased in blood of cancer patients. It is decreased in all cancers tested which include lung cancer, biliary track cancer, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, brain tumor, renal cancer, liver cancer, and cervical cancer.
Recurrence Monitoring Case 1 : Colon Cancer
Recurrence Monitoring Case 2 : Pancreatic Cancer
YN522 is decreased at the time of cancer developing. It shows same decline in early stage which makes it useful biomarker in early cancer detection and monitoring recurrence.
YN522 and 6 additional biomarkers included in patent show extremely high sensitivity and specificity on all types of cancer and recurrence of them. Other previous biomarkers can be added to test for even more sensitivity and specificity.